Showing 1,281 - 1,300 results of 10,824 for search 'significantly ((((lower decrease) OR (we decrease))) OR (((teer decrease) OR (mean decrease))))', query time: 0.57s Refine Results
  1. 1281
  2. 1282

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”
  3. 1283

    Original data2. by Lan Zeng (638254)

    Published 2025
    “…<div><p>Diabetic retinopathy (DR) is a leading cause of blindness. We hypothesised that the long non-coding RNA <i>RP11-502I4.3</i> may be involved in angiogenesis associated with DR. …”
  4. 1284

    Original data1. by Lan Zeng (638254)

    Published 2025
    “…<div><p>Diabetic retinopathy (DR) is a leading cause of blindness. We hypothesised that the long non-coding RNA <i>RP11-502I4.3</i> may be involved in angiogenesis associated with DR. …”
  5. 1285
  6. 1286

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  7. 1287

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  8. 1288

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  9. 1289
  10. 1290
  11. 1291
  12. 1292

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  13. 1293
  14. 1294
  15. 1295
  16. 1296
  17. 1297
  18. 1298
  19. 1299
  20. 1300